{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
icosapent ethyl
to a specific field?
Class (Stereo):
CHEMICAL (ABSOLUTE)
Tamethicillin is a basic ester pro-drug of methicillin (MET) which is converted in the body by non-specific esterases to MET. Tamethicillin was used as an antibacterial agent in the veterinary as a useful alternative for the treatment of mastitis in livestock, especially in mastitis due to beta-lactamase-producing Staphylococcus.
Class (Stereo):
CHEMICAL (ACHIRAL)
Melquinast is an antiasthmatic, antiallergic substance not acting primarily as antihistamines.
Status:
Investigational
Source:
NCT00743925: Phase 2 Interventional Completed Acute Coronary Syndrome
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Varespladib (LY315920; A-001) is a potent and selective inhibitor of IIa, V, and X isoforms of human non-pancreatic secretory phospholipase A2 with nM IC50. The molecule acts as an anti-inflammatory agent by disrupting the first step of the arachidonic acid pathway of inflammation. Varespladib methyl is being developed by Anthera Pharmaceuticals Inc for the potential treatment of coronary artery disease, acute coronary syndrome and inflammation. Varespladib methyl is a prodrug that is rapidly metabolized to varespladib, and both compounds are able to potently inhibit the enzymes of the human secretory phospholipase groups. Phase II clinical trials of varespladib methyl in patients with coronary artery disease, rheumatoid arthritis, asthma and ulcerative colitis revealed that the drug was well tolerated. Varespladib methyl did not demonstrate a good efficacy profile in patients with rheumatoid arthritis, asthma and ulcerative colitis; whereas in patients with coronary artery disease, varespladib methyl consistently reduced LDL-cholesterol levels, (elevated LDL-cholesterol levels are a marker of increased cardiovascular risk). Varespladib methyl could represent a novel therapy for the treatment of cardiovascular disease, although the efficacy, safety profile and advantages of this drug compared with existing therapeutic options would need to be established in upcoming phase III trials.
Class (Stereo):
CHEMICAL (ACHIRAL)
Glicondamide is a derivative of sulphonamides (antibacterial sulfa drugs). It acts by increasing the release of insulin from pancreatic beta cells, resulting in lower blood glucose levels.
Status:
Investigational
Source:
NCT01300208: Phase 2 Interventional Completed Cutaneous Lupus Erythematosus
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Class (Stereo):
CHEMICAL (ABSOLUTE)
Dexpemedolac is long-acting non-narcotic analgesic. Dexpemedolac exhibited potent analgesic effects against chemically induced pain in rats and mice and against inflammatory pain in rats. Dexpemedolac differed from standard nonsteroidal anti-inflammatory drugs (NSAIDs) in that the doses, which produced analgesia were much lower than those required for either anti-inflammatory or gastric irritant effects. The common to the NCAIDs class actions are antipyresis and inhibitory effects on platelet aggregation. In yeast-induced hyperthermic rats, dexpemedolac exhibited antipyretic actions, whereas the drug did not affect body temperature in normothermic animals. Aggregation of human platelets was inhibited by high concentrations of dexpemedolac.
Status:
Investigational
Source:
INN:fencibutirol [INN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Fencibutirol is alpha-cyclohexylbutyric acid derivative. It exerts choleretic activity.
Status:
Investigational
Source:
NCT00803556: Phase 1 Interventional Completed Solid Tumor
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Alvespimycin (17-desmethoxy-17-N,N-dimethylaminoethylamino-geldanamycin) (17-DMAG; NSC 707545) is an inhibitor of the molecular chaperone heat shock protein HSP90. Alvespimycin is a derivative of antineoplastic benzoquinone antibiotic geldanamycin. Alvespimycin binds to HSP90, a chaperone protein that aids in the assembly, maturation and folding of proteins. Subsequently, the function of Hsp90 is inhibited, leading to the degradation and depletion of its client proteins such as kinases and transcription factors involved with cell cycle regulation and signal transduction. Alvespimycin was studied in clinical trials for the treatment of solid tumors and hematologic malignancies however its development was discontinued.
Status:
Investigational
Source:
NCT00804570: Phase 2 Interventional Completed Alcohol Dependence
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Ondelopran (also known as LY2196044) was developed as orally available opioid receptor antagonist for the treatment of alcoholism. This drug completed clinical trials phase III where was assess its efficacy and safety in the treatment of alcohol dependence in adult outpatients.
Class (Stereo):
CHEMICAL (ACHIRAL)
IRLOXACIN, a fluorinated quinolone derivative, is an antibacterial agent with proved activity against both gram-positive and gram-negative bacteria.
